

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 4, 2018

**SECOND SIGHT MEDICAL PRODUCTS, INC.**  
(Exact Name of Registrant as Specified in Its Charter)

**California**  
(State or Other Jurisdiction of Incorporation)

**333-198073**  
(Commission File Number)

**02-0692322**  
(IRS Employer Identification No.)

**12744 San Fernando Road, Suite 400**  
**Sylmar, California 91342**  
(Address of Principal Executive Offices)

**(818) 833-5000**  
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## ITEM 7.01. REGULATION FD DISCLOSURE

A copy of a slide presentation that Second Sight Medical Products, Inc. ("Second Sight") intends to use during a presentations made at the Annual B. Riley FBR Healthcare Conference on September 4, 2018, and at the H.C. Wainwright 20<sup>th</sup> Annual Global Investment Conference on September 6, 2018, (the "Presentation Materials"), is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated by reference herein. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Second Sight may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Second Sight specifically disclaims any obligation to do so. Additionally, the H.C. Wainwright 20<sup>th</sup> Annual Global Investment Conference presentation will be webcast at 12:30 P.M. Eastern Daylight Time at <http://wsw.com/webcast/rshq28/eyes/>. The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company's website at [www.secondsight.com](http://www.secondsight.com), under the Investor Relations section. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

## ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

### Exhibit No. Description

99.1 [Second Sight Medical Products, Inc. Investor Presentation dated September 4, 2018](#)

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 4, 2018

### SECOND SIGHT MEDICAL PRODUCTS, INC.

/s/ John T. Blake  
By: John T. Blake  
Chief Financial Officer



NASDAQ: EYES

---

**Enriching the Lives of the Blind**  
September 2018

---



# Forward Looking Statements


This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans," or "planned," "seeks," "may," "will," "expects," "intends," "believes," "should," and similar expressions, or the negative versions thereof, and which also may be identified by their context. All statements that address operating performance or events or developments that Second Sight expects or anticipates will occur in the future, such as stated objectives or goals, or that are not otherwise historical facts, are forward-looking statements. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report, on Form 10-K, filed on March 20, 2018, our most recent 10-Q, filed on August 7, 2018 and our other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto, or any change in events, conditions, or circumstances on which any such statement is based.



# Two Breakthrough Technologies


## Argus® II retinal prosthesis

- First and only FDA approved retinal prosthesis
- 20+ years and ~\$200 million invested to develop and commercialize
- Established technology with 293+ implants
- Approved for individuals with retinitis pigmentosa (bare-light and no-light perception in U.S.)



## Orion™ visual cortical prosthesis system

- Leveraging Argus II technology
- Bypasses the retina and optic nerve to directly stimulate the brain
- Transformational technology with human trial initiated Q1 2018
- Broad label potential including:
  - Glaucoma, diabetic retinopathy, optic nerve disease and trauma




# Argus<sup>®</sup> II: Effective Treatment for Blindness

NASDAQ: EYES



**Argus II** is a retinal prosthesis that induces visual perception in individuals with severe to profound retinitis pigmentosa (RP)







# Orion is our Strategic Priority



## Execute clinical and R&D programs

- 6 subject feasibility study at UCLA and Baylor ongoing
- FDA Breakthrough Device designation for expedited path
- Projects underway to iterate implant design and externals in preparation for pivotal trial



## Commercial focus on capital efficiency & leverage

- Markets and activities with near-term ROI and highest impact
- Centers of excellence strategy to build sustainable business model
- Market development and artificial vision rehab competencies required for Argus and Orion



## Research projects to improve user experience


- Technologies in research phase, many with partners, to enhance visual acuity or create a richer user experience
- Examples include object & facial recognition, distance filtering, thermal imaging and eye tracking
- Technologies applicable to Argus and Orion platforms



# Orion: Designated as Breakthrough Device

***Leveraging Argus II technology, our breakthrough Orion platform bypasses the damaged eye and/or optic nerve to directly stimulate the brain***

- Orion has the potential to treat many forms of blindness including glaucoma, diabetic retinopathy, optic nerve disease and trauma
- Received FDA Breakthrough Device designation
  - Expedited clinical and regulatory path to U.S. commercialization
- Third-party market research validates robust market size for Orion in U.S.



**Market outside US expected to be larger than U.S.  
*Orion is potentially a multi-billion dollar market opportunity***





- Conducting a six subject feasibility study at **UCLA Medical Center** and the **Baylor College of Medicine**
  - Five subjects implanted and activated in 1H 2018
  - All report seeing spots of light on virtually all electrodes
- Observations from our early testing include the following:
  - Stimulation parameters are within expected ranges and are generally stable
  - Spatial maps vary by subject and are generally stable over time
  - Field of view appears to be larger than Argus
  - Several subjects are undergoing direction of motion testing and early test results are encouraging
  - Device reliability and performance have been good



# Orion Leverages Argus Experience & Technology

## COE model and artificial vision rehabilitation

- Centers of Excellence model to build regional Argus centers
- Best practices development and pioneered post-surgical rehabilitation to improve patient satisfaction and outcomes



## Effective patient outreach & screening with U.S. patient database

- Effective patient outreach programs & a multi-step patient qualification process
- Large & growing U.S. patient database that includes potential Argus and Orion patients



## Market access & reimbursement expertise

- Established therapy in over a dozen markets worldwide
- Highest CMS outpatient reimbursement rate in U.S.
- First device accepted in Forfait Innovation program in France



## Argus II technology platform

- Established technology with 10 years+ experience implant durability
- Proprietary algorithms for artificial vision, leverage into Orion





## Execute Argus business with capital efficiency

- High bar for new markets or expansion in current markets
- Improve cost structure and utilization of commercial team
- Focus on Centers of Excellence



## Develop Argus commercial competencies that are strategic for Orion

- Patient outreach, patient qualification & U.S. patient database
- Artificial vision rehabilitation expertise



## Invest in Argus R&D that benefits Orion

- Argus externals including eyewear, camera and VPU
- Software and proprietary software/algorithms used to create artificial vision



## Eye tracking

- Move the implant field of view in conjunction with the movement of the user's eyes

## Thermal imaging

- Infrared imaging would allow users to visualize warm objects such people in a room



## Depth based decluttering


- Allow users to filter out objects further than a defined distance

## Object recognition

- Receive additional auditory and/or haptic information integrated with their artificial vision



# Key Drivers of Shareholder Value through 2019







# Select Financial Data

(USD \$ in thousands)	Q2 2018	FY 2017	FY 2016
<b>Implants</b>	<b>17</b>	<b>75</b> <i>(30 in Q4)</i>	<b>42</b> <i>(7 in Q4)</i>
Revenue	\$1,907	\$7,964	\$3,985
Gross Profit (Loss)	\$1,071	\$2,847	\$(6,091)
Net Loss	\$(7,961)	\$(28,516)	\$(33,179)
Non-GAAP Adjusted Net Loss <sup>1</sup>	\$(7,120)	\$(27,576)	\$(24,812)

(USD \$ in thousands)	June 30, 2018	December 31, 2017
Cash and cash equivalents	\$7,476	\$7,839
<b><i>Raised \$15.0 million in 2018 from private placement transactions (May and August)</i></b>		
Debt	\$0	\$0







# Second Sight Investment Highlights

- **Argus II business focused on capital efficiency and strategic benefit**
  - ROI and cost structure improvements important when evaluating markets or expansion
  - Commercial competencies and R&D efforts such as Argus 2s next-gen externals that benefit Orion are prioritized
- **Orion is a large market opportunity that's more than 50x the current RP market**
  - Potential to treat nearly all forms of blindness including diabetic retinopathy, glaucoma, optic nerve disease and eye injury
  - Six subject feasibility study at UCLA and Baylor underway with good early results and interim data in next 6 months
  - FDA Breakthrough Device designation provides expedited regulatory and clinical pathway
- **Orion leverages Argus**
  - Orion leverages Argus technology including implantable array, externals and proprietary software / algorithms for creating artificial vision
  - Orion also leverages reimbursement success, patient outreach & screening expertise as well as artificial vision rehabilitation competencies
- **Future technologies under development beneficial to Argus and Orion**
  - Eye-tracking, thermal imaging and depth-based decluttering provide improved or more useful vision
  - Object recognition and facial recognition create enhanced user experience



## **Second Sight Medical Products, Inc.**

12744 San Fernando Road  
Suite 400

Sylmar, CA 91342

Main: 818-833-5000

[www.secondsight.com](http://www.secondsight.com)

Will McGuire

President & CEO

Direct: 818-833-5040

[wmcguire@secondsight.com](mailto:wmcguire@secondsight.com)

### **Retail Investor Relations**

Greg Falesnik

Managing Director

MZ North America

Direct: 949-385-6449

[Greg.Falesnik@mzgroup.us](mailto:Greg.Falesnik@mzgroup.us)

### **Institutional Investor Relations**

Lisa Wilson

President

In-Site Communications, Inc.

Direct: 212-452-2793

[lwilson@insitecony.com](mailto:lwilson@insitecony.com)

